Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

64 results about "Metered-dose inhaler" patented technology

A metered-dose inhaler (MDI) is a device that delivers a specific amount of medication to the lungs, in the form of a short burst of aerosolized medicine that is usually self-administered by the patient via inhalation. It is the most commonly used delivery system for treating asthma, chronic obstructive pulmonary disease (COPD) and other respiratory diseases. The medication in a metered dose inhaler is most commonly a bronchodilator, corticosteroid or a combination of both for the treatment of asthma and COPD. Other medications less commonly used but also administered by MDI are mast cell stabilizers, such as cromoglicate or nedocromil.

Pharmaceutical compositions comprising RPL554 in HFA-134a for administration by inhalation

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) a suspension of particles comprising 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) a diluent which is 1,1,1,2-tetrafluoroethane (HFA-134a), wherein the liquid pharmaceutical composition is substantially free of surfactant. The invention also relates to a pressurised metered dose inhaler comprising the liquid pharmaceutical composition.
Owner:VERONA PHARMA

Portable holding chamber

A medication delivery system having a holding chamber capable of delivering dosages of medicament from a metered dose inhaler. The holding chamber includes a first housing component having a user interface with an outlet opening and a second housing component having an inlet opening spaced apart from the outlet opening of the first housing component. The first housing component is pivotally connected to the second housing component about a pivot axis.
Owner:TRUDELL MEDICAL INT INC

Automatic shaking type air suction driving quantitative inhaler

The invention discloses an automatic shaking type air suction driving quantitative inhaler. Comprising a shell, an electric pressing mechanism arranged in the shell, a tank body connected with the electric pressing mechanism, a reset mechanism arranged at the bottom in the shell, a reciprocating motion mechanism connected with the reset mechanism, a suction nozzle connected with the tank body, a suction nozzle cover arranged on the suction nozzle and an OLED display screen arranged on the shell, and the reciprocating motion mechanism is connected with the tank body. An air flow sensor is arranged at the bottom of the tank body and located on one side of the suction nozzle, a self-reset button is arranged on one side of the reciprocating mechanism and connected with the OLED display screen, the reset mechanism is installed at the bottom of the shell, and the electric pressing mechanism, the reciprocating mechanism, the air flow sensor and the OLED display screen are connected with the control module. The invention has the beneficial effects that the administration efficiency is improved, and the treatment effect is improved.
Owner:SUZHOU HAIXI INTELLIGENT MEDICAL TECH CO LTD

Compositions for respiratory delivery of active agents and associated methods and systems

Compositions, methods and systems are provided for pulmonary or nasal delivery of active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
Owner:PEARL THERAPEUTICS INC

Methods, devices and systems for pulmonary delivery of active agents

Provided herein is a method of pulmonary delivering to a subject at least one pharmacologically active agent being in a plant material, which is effected by pulmonary delivering the agent to the subject using a metered dose inhaler device that is configured to vaporize at least one pre-determined vaporized amount of the agent upon controllably heating the plant material, wherein the pre-determined vaporized amount is selected so as to achieve at least one pre-determined pharmacokinetic effect and / or at least one pre-determined pharmacodynamic effect induced by the agent in the subject.
Owner:SYQE MEDICAL LTD

Nicotine formulation

This disclosure relates to an improved inhalable formulation comprising nicotine, or a pharmaceutically acceptable derivative or salt thereof, a propellant, a C1 to C6 alcohol and a glycol. The disclosure further relates to a metered dose inhaler containing the inhalable nicotine formulation and a method of treating a nicotine addiction with the formulation.
Owner:INHALER SUPPLIES PTY LTD

Inhalable formulation

This disclosure relates to an inhalable formulation comprising melatonin and, optionally, a cannabinoid. Furthermore, this disclosure relates to a metered dose inhaler containing the inhalable formulation and methods and uses of the inhalable formulation.
Owner:MORPHEUS THERAPEUTICS PTY LTD

Drug delivery systems and related methods

ActiveUS12714808B2Pharmacy medicineDesiccant
Systems and methods for isolating and / or desiccating a portion of a drug delivery tract of a drug delivery apparatus to reduce water vapor content therein are provided. For example, there is provided a metered dose inhaler for delivering aerosolized medicament or other matter to a user. The aerosolized medicament or other matter may be discharged from a discharge passageway within the inhaler into an inhalation passageway for inhalation by a user, and the inhaler may comprise a seal member operative to selectively isolate the discharge passageway from the inhalation passageway and external environment during inactivity. The inhaler may further comprise a desiccant material arranged to withdraw moisture from the isolated discharge passageway. In other instances, desiccant material may be arranged to withdraw moisture from the discharge passageway of the inhaler without isolating the discharge passage during inactivity.
Owner:PEARL THERAPEUTICS INC

Medication delivery system

A medication delivery system having a holding chamber capable of delivering dosages of medicament from a metered dose inhaler. The holding chamber includes an actuator detector, flow detector and display. In another embodiment, a medication delivery system includes a holding chamber having an input and an output end, a metered dose inhaler operably coupled to the input end of the holding chamber, and a metered dose inhaler identifier associated with the holding chamber and operable to identify the metered dose inhaler coupled to the holding chamber.
Owner:TRUDELL MEDICAL INT INC

Device, methods and uses for treating anaphylaxis

The present disclosure provides a metered dose inhaler (MDI) comprising an API formulation suitable for administration to a patient in need thereof by inhalation, as well as methods and uses of the MDI.
Owner:KOKUA PHARMA INC

Stainles steel can for pressurised metered dose inhalers

The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.
Owner:CHIESI FARMACEUTICI SPA

Drug delivery device

Metered dose inhaler device including an actuator housing (10) with a substantially hollow first portion (15) including a nozzle block, and a substantially hollow second portion (25) defining a mouthpiece and located adjacent the substantially hollow first portion. A spray orifice (45) is formed in the nozzle block (30). The spray orifice (45) defines a jet length (46) along an orifice axis. The spray orifice defines an orifice exit (49) with an orifice exit diameter (47). The jet length is at least 0.8 millimeters ("mm"). The device includes a composition including a propellant that includes 1,1-difluoroethane ("HFA-152a") or trans-1, 1,1,3-tetrafluoropropene ("HFO-1234ze(E) "), the composition located in a canister (40) disposed in the substantially hollow first portion (15). Once the composition is ejected from the orifice exit (49), the composition defines a spray pattern. The spray pattern matches that of a similar device using a propellant including 1,1,1,2,3,3,3-heptafluoropropane ("HFA-227") and a jet length less than or equal to 0.8 mm.
Owner:STEIN STEPHEN +7

Tiotropium formulation and inhaler

A metered dose inhaler equipped with a metering valve and having an aerosol canister containing a pharmaceutical composition comprising propellant, ethanol, citric acid, and tiotropium or a pharmaceutically acceptable salt or solvate thereof dissolved in the composition, wherein the aerosol canister has an internal surface that is a non-metal material that is in contact with the pharmaceutical composition.
Owner:KINDEVA DRUG DELIVERY LP

Improved pharmaceutical aerosol formulation

To provide a pharmaceutical aerosol formulation for use in a pressurized metered dose inhaler (abbreviated as pMDI or MDI), particularly an improved pharmaceutical aerosol formulation for aerosol administration.SOLUTION: The present invention provides a pharmaceutical aerosol suspension formulation for MDI administration, comprising: (a) an atomization β2-stimulant, (b) micronized corticosteroid, (c) a quasi-therapeutic amount of a moisture scavenging excipient, and (d) an HFA propellant. The (a), (b) and (c) and their respective relevant amounts are selected such that they associate to form fluorocarbon having substantially the same density as that of the HFA (hydrofluoroalkane) propellant.SELECTED DRAWING: None
Owner:JAGOTEC AG

Stable adrenaline suspension formulations with HFO propellants for inhalation

A pharmaceutical aerosol formulation containing pre-micronized epinephrine, a co-solvent ethanol, a surfactant polysorbate 80, and a propellant trans-1, 3, 3, 3-tetrafluoropropene (HFO-1234ze (E)) for use in a pressurized metered dose inhaler is described. The formulations provide efficient delivery of pre-micronized epinephrine particles into the respiratory tract of a patient, and have the advantages of high therapeutic efficacy, improved safety, and low global warming potential (GWP) affecting the environment.
Owner:AMPHASTAR PHARMACEUTICALS INC

Quantitative aerosol inhalation system

The invention provides a quantitative aerosol inhalation system, which comprises a mouthpiece, a tee joint, a filter, an atomization device, an electromagnetic valve and a one-way valve, and is characterized in that the system is arranged in the tee joint, when a user exhales from the mouthpiece, the one-way valve is opened, airflow flows out of the filter through the one-way valve, when the user inhales, the one-way valve is closed, and the user can only inhale gas flowing in from the atomization device; and the control module is used for receiving the gas pressure value detected by the pressure detection element and controlling the action of the electromagnetic valve according to the gas pressure value. By means of the quantitative aerosol inhalation system, it can be ensured that aerosol administration is conducted on each patient under the optimal inhalation flow, once the inhalation flow is lower than the optimal flow range, administration is stopped immediately, and the accuracy of aerosol administration is greatly improved; meanwhile, the unique one-way valve design is adopted, and cross infection is eradicated; the dosing dosage can be automatically calculated, so that different dosing dosages can be generated by using a single concentration, and the gallipot does not need to be frequently replaced.
Owner:ZHEJIANG KELUODE HEALTH TECH CO LTD

Compositions, methods and systems for aerosol drug delivery

1. A pharmaceutical composition deliverable from a metered dose inhaler, the pharmaceutical composition comprising: a propellant of pharmaceutical grade 1,1-Difluoroethane (HFC-152a); a plurality of active agent particles; and a plurality of phospholipid particles comprising perforated microstructures; wherein the active agent particles comprise an active agent selected from a long-acting muscarinic antagonist (LAMA), a long-acting P2-agonist (LABA), a short-acting beta-agonist (SABA), an inhaled corticosteroid (ICS), and a non-corticosteroid anti-inflammatory agent. A metered dose inhaler comprising a canister with an outlet valve including an actuator for dispensing a metered amount of said pharmaceutical composition, wherein the canister contains the pharmaceutical composition. Said composition for use in the treatment of a pulmonary disease or disorder.
Owner:ASTRAZENECA AB

Metered dose inhaler canister with improved sealing arrangement

A metered dose inhaler valve (26) has a reservoir portion (37) for assembly with a canister (14) for receiving a pressurised formulation of medicament and propellant, a metering valve body (96) defining a metering chamber, and a metering valve stem (24) having an outlet (56) and being axially moveable within the body. The stem moves between a first position in which the chamber is in fluid communication with the canister, and a second position in which the chamber is in fluid communication with the valve stem outlet. A metering valve seal is defined by the valve body and includes an opening through which the stem passes to form a dynamic seal between the stem and at least one of the outside atmosphere and the pressurized canister, where the opening is adapted to be stretched wider by the stem passing through it than it would be absent the valve stem.
Owner:BUNTING JOHN P +3

A metered dose inhaler

The application provides a quantitative injection device, and relates to the technical field of medical injection devices. The quantitative injection device comprises a shell, a dose sleeve, an indicating piece, a rotating assembly, a push rod assembly and a threaded sleeve. The dose sleeve is sleeved on the shell, the rear end of the dose sleeve is provided with a first ratchet, and the dose sleeve is in threaded transmission with the shell. The indicating piece is installed on the shell, and is used for indicating the dose of a medicament. The rotating assembly is installed on the dose sleeve, the rotating assembly is provided with a second ratchet which is engaged with the first ratchet, and the front end of the rotating assembly is provided with a third ratchet. The push rod assembly is installed on the rotating assembly, the push rod assembly is provided with a fourth ratchet which is engaged with the third ratchet, and the rotating assembly can drive the push rod assembly to rotate. The push rod assembly can move in the front-rear direction relative to the threaded sleeve. The embodiment of the application can solve the problem that the injection dose cannot be steplessly adjusted.
Owner:SUZHOU TIANHE YUNDUO MEDICAL TECH CO LTD

Respiratory care system with electronic indicator

ActiveCN115779207BRespiratory masksMedical devicesExpiratory valveRespiratory care
A respiratory delivery care system is characterized by comprising: a mechanical flow indicator movable in response to a user's inhalation and / or exhalation, and an electronic indicator operable in response to an electronic signal transmitted in response to the movement of the flow indicator. The flow indicator is an inspiratory valve, an expiratory valve, or an axially movable actuator. The delivery device includes a retaining chamber wound with a coil and at least one magnet disposed at the center of the coil, the at least one magnet being reciprocating to sense current and store the current in a supercapacitor connected to the circuitry and the electronic indicator. A respiratory delivery device is characterized by comprising: a flow indicator configured to transmit a first input signal, a metered-dose inhaler in communication with the retaining chamber, a lever for actuating the inhaler and having a sensor to transmit a second input signal, and a processor for receiving these signals to generate an output signal.
Owner:TRUDELL MEDICAL INTERNATIONAL INC LONDON

Combination of albuterol and budesonide for the treatment of asthma

The present disclosure provides a method of treating asthma in a subject at risk of asthma exacerbation, and a method of as-needed treatment or prevention of bronchoconstriction in a subject, and / or prevention of exacerbation in a subject with asthma, comprising administering as needed to the subject a composition comprising therapeutically effective amounts of albuterol and budesonide, wherein the composition is administered via a metered dose inhaler, wherein the method reduces risk of severe asthma exacerbation by at least about 15% as compared to administration of a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation. Also provided is a pharmaceutical composition comprising: albuterol and budesonide in the form of particles; a suspension medium comprising a hydrofluoroolefins (HFO) propellant and / or a hydrofluorocarbon propellant (HFC), and a plurality of respirable suspending particles, wherein the particles of albuterol and budesonide associate with the plurality of respirable suspending particles.
Owner:ASTRAZENECA AB

Propellants for anticholinergic agents in pressurized metered dose inhalers

PendingUS20250009653A1Dispersion deliveryAerosol deliveryAnticholinergic DrugsAnticholinergic agents
A composition comprising a solution comprising an active pharmaceutical ingredient comprising an anticholinergic agent, such as ipratropium bromide, and a propellant comprising HFA-152a, HFO-1234ze(E), or both. A metered dose inhaler comprising a metering valve a canister; and an actuator comprising an actuator nozzle; wherein the canister comprises said composition.
Owner:KINDEVA DRUG DELIVERY LP

Pressurized metered dose inhaler comprising buffered pharmaceutical formulation

The present invention generally relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, the formulation being contained in a coated canister, which formulation is particularly useful for use in pressurized metered dose inhalers for the treatment of respiratory diseases.
Owner:CHIESI FARMACEUTICI SPA

Stable pharmaceutical compositions for pressurized metered dose inhalers

The present invention provides a stable pharmaceutical composition to be used with pressurized metered dose inhalers comprising a beta 2 agonist, a corticosteroid, a muscarinic antagonist, HFO propellant, a co-solvent, an organic acid(s) and optionally water. The invention further provides a specific container and a valve system comprising internally coated canister and a valve for storing the composition. The invention also provides a pharmaceutical composition comprising a beta 2 agonist, a corticosteroid, a muscarinic antagonist for the treatment or prophylaxis of asthma, chronic obstructive pulmonary disease (COPD), rhinitis or as adjunct therapy for cystic fibrosis, non-cystic fibrosis bronchiectasis, lung infections or pulmonary fibrosis.
Owner:LUPIN INC

Portable holding chamber

A medication delivery system having a holding chamber capable of delivering dosages of medicament from a metered dose inhaler. The holding chamber includes a first housing component having a user interface with an outlet opening and a second housing component having an inlet opening spaced apart from the outlet opening of the first housing component. The first housing component is pivotally connected to the second housing component about a pivot axis.
Owner:TRUDELL MEDICAL INT INC

Adherence-tracking and monitoring device for metered-dose inhaler

An adherence-monitoring and tracking device captures usage of a metered dose inhaler (MDI). The device includes an enclosure for enclosing a metered dose inhaler (MDI), and an electro-mechanical system forming a part of enclosure to sense and log the operation of the MDI. The electro-mechanical system includes at-least one transducer to capture one or more parameters pertaining to an operation of the MDI by the user. A microcontroller processes the captured parameters, and an output-unit renders data pertaining to operation of the MDI.
Owner:CIPLA LTD

Gold-Containing Agents For The Treatment Of Lung Infections

PendingAU2026205378A1DiseasePowder Inhaler
The present invention relates to pharmaceuticals for inhalation, containing aurothioglucose, and to an inhaler, preferably a powder inhaler, dosing inhaler or atomizer containing such pharmaceuticals. The invention provides these pharmaceuticals for use in the prevention and therapy of pulmonary diseases, in particular infectious and inflammatory-infectious pulmonary diseases. 20 26 20 53 78 07 J ul 2 02 6 2 0 2 6 2 0 2 6 2 0 5 3 7 8 0 7 J u l
Owner:AUROVIR PHARMA GMBH

Ipratropium delivery compositions, devices and methods

PCT designated stageWO2026060453A1Dispersion deliveryOrganic non-active ingredientsAerosol sprayIpratropium bromide
The present invention relates to a pressurized metered dose inhaler (pMDI) comprising: a container; a pharmaceutical formation under pressure in the container, said pharmaceutical formulation comprising: (i) about from about 75% by weight to about 87% by weight HFO-1234ze(E); (ii) from about 13% by weight to about 25% by weight of ethanol; and (iii) ipratropium bromide in solution in said ethanol and / or said HFO-1234ze(E); a normally closed valve on the container; and an actuator fluidly connected to the valve and having an orifice diameter of less than 0.5 mm, said valve being actuatable to an open position to release said pharmaceutical formulation to pass through said orifice and produce an aerosol spray containing ipratropium bromide in solution.
Owner:SOLSTICE ADVANCED MATERIALS US INC